{"title": "Efectividad y Seguridad de la Vacunaci\u00f3n COVID-19 para Pacientes con Enfermedad Hep\u00e1tica (CHESS2101)", "author": "Xiaolong Qi", "url": "https://ichgcp.net/es/clinical-trials-registry/NCT04883177", "hostname": "ichgcp.net", "description": "La pandemia de COVID-19 con infecci\u00f3n por SARS-CoV-2 se ha convertido en un desaf\u00edo global. Aunque la mayor\u00eda de los casos de COVID-19 son leves, la enfermedad.... Registro de ensayos cl\u00ednicos. ICH GCP.", "sitename": "ichgcp.net", "date": "2021-04-29", "id": null, "license": null, "body": null, "comments": "", "commentsbody": null, "raw_text": null, "text": "Efectividad y Seguridad de la Vacunaci\u00f3n COVID-19 para Pacientes con Enfermedad Hep\u00e1tica (CHESS2101)\n23 de abril de 2023 actualizado por: Xiaolong Qi,\n[Hepatopancreatobiliary Surgery Institute of Gansu Province](https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Hepatopancreatobiliary%20Surgery%20Institute%20of%20Gansu%20Province)\nEficacia y seguridad de la vacunaci\u00f3n contra la COVID-19 para pacientes con enfermedad hep\u00e1tica (CHESS2101): un estudio de cohorte multic\u00e9ntrico\nLa pandemia de COVID-19 con infecci\u00f3n por SARS-CoV-2 se ha convertido en un desaf\u00edo global. Aunque la mayor\u00eda de los casos de COVID-19 son leves, la enfermedad tambi\u00e9n puede ser fatal. Los pacientes con enfermedad hep\u00e1tica son m\u00e1s susceptibles al da\u00f1o de la infecci\u00f3n por SARS-CoV-2 considerando su estado inmunocomprometido. Por lo tanto, la inoculaci\u00f3n temprana de la vacuna contra el SARS-CoV-2 en pacientes con enfermedad hep\u00e1tica es una medida de protecci\u00f3n importante. Sin embargo, queda por determinar la informaci\u00f3n sobre la eficacia y la seguridad de la vacuna COVID-19 para la enfermedad hep\u00e1tica. Este estudio multic\u00e9ntrico (CHESS2101) tiene como objetivo estudiar la efectividad y seguridad de la vacunaci\u00f3n contra el COVID-19 para pacientes con enfermedad hep\u00e1tica.\nDescripci\u00f3n general del estudio\nEstado\nTerminado\nCondiciones\nDescripci\u00f3n detallada\nLos pacientes con enfermedad hep\u00e1tica, especialmente cirrosis hep\u00e1tica, neoplasias hepatobiliares, candidatos para trasplante de h\u00edgado y personas inmunodeprimidas despu\u00e9s de un trasplante de h\u00edgado, tienen un mayor riesgo de infecci\u00f3n por COVID-19 y una mayor mortalidad. Por lo tanto, la inoculaci\u00f3n temprana de la vacuna contra el SARS-CoV-2 en pacientes con enfermedad hep\u00e1tica es una medida de protecci\u00f3n importante. Una peque\u00f1a cantidad de vacunas contra el SARS-CoV-2 se han probado en ensayos cl\u00ednicos en individuos sanos y tienen evidencia de seguridad, inmunogenicidad y eficacia a corto plazo. Sin embargo, queda por determinar la informaci\u00f3n sobre la eficacia y seguridad de la vacuna COVID-19 para pacientes con enfermedad hep\u00e1tica. Este estudio multic\u00e9ntrico (CHESS2101) tiene como objetivo estudiar la efectividad y seguridad de la vacunaci\u00f3n contra el COVID-19 para pacientes con enfermedad hep\u00e1tica.\nTipo de estudio\nDe observaci\u00f3n\nInscripci\u00f3n (Actual)\n1000\nContactos y Ubicaciones\nEsta secci\u00f3n proporciona los datos de contacto de quienes realizan el estudio e informaci\u00f3n sobre d\u00f3nde se lleva a cabo este estudio.\nEstudio Contacto\n- Nombre: Jitao Wang, MD\n- N\u00famero de tel\u00e9fono: +8618632957579\n- Correo electr\u00f3nico:\n[wangjt302@163.com](mailto:wangjt302@163.com?subject=NCT04883177, CHESS2101, Effectiveness and Safety of the COVID-19 Vaccination for Patients With Liver Disease (CHESS2101))\nUbicaciones de estudio\n-\nPorcelana\n-\nAnhui\n-\nHefei, Anhui, Porcelana\n- The First Affiliated Hospital of Anhui Medical University\n-\n-\nBeijing\n-\nBeijing, Beijing, Porcelana\n- Beijing You'an Hospital\n-\n-\nChongqing\n-\nChongqing, Chongqing, Porcelana\n- The First Affiliated Hospital of Chongqing Medical University\n-\nChongqing, Chongqing, Porcelana\n- Chongqing Fuling Central Hospital\n-\n-\nFujian\n-\nXiamen, Fujian, Porcelana\n- The First Affiliated Hospital of Xiamen University\n-\n-\nGansu\n-\nJinchang, Gansu, Porcelana\n- Jinchang Central Hospital\n-\nLanzhou, Gansu, Porcelana, 730000\n- The First Hospital of Lanzhou University\n-\nQingyang, Gansu, Porcelana\n- Qingyang People's Hospital\n-\n-\nGuangdong\n-\nGuangzhou, Guangdong, Porcelana\n- The Third Affiliated Hospital of Sun Yat-sen University\n-\n-\nHebei\n-\nXingtai, Hebei, Porcelana\n- Xingtai People's Hospital\n-\n-\nHeibei\n-\nBaoding, Heibei, Porcelana\n- Baoding People's Hospital\n-\n-\nHenan\n-\nZhengzhou, Henan, Porcelana\n- Henan Provincial People's Hospital\n-\n-\nHubei\n-\nWuhan, Hubei, Porcelana\n- Wuhan Jinyintan Hospital\n-\n-\nJiangsu\n-\nTaicang, Jiangsu, Porcelana\n- The First People's Hospital of Taicang\n-\nWuxi, Jiangsu, Porcelana\n- Wuxi Fifth People's Hospital\n-\nZhenjiang, Jiangsu, Porcelana\n- The Affiliated Third Hospital of Jiangsu University\n-\n-\nLiaoning\n-\nJinzhou, Liaoning, Porcelana\n- Jinzhou Central Hospital\n-\nShenyang, Liaoning, Porcelana\n- Sixth People's Hospital of Shenyang\n-\n-\nNingxia Hui Autonomous Region\n-\nYinchuan, Ningxia Hui Autonomous Region, Porcelana\n- People's Hospital of Ningxia Hui Autonomous Region\n-\n-\nShandong\n-\nJinan, Shandong, Porcelana\n- Shandong Provincial Hospital\n-\nQingdao, Shandong, Porcelana\n- Qingdao Sixth People's Hospital\n-\nYantai, Shandong, Porcelana\n- Qishan Hospital of Yantai City\n-\n-\nShanghai\n-\nShanghai, Shanghai, Porcelana\n- Huashan Hospital affiliated to Fudan University\n-\n-\nShanxi\n-\nJincheng, Shanxi, Porcelana\n- Jincheng People's Hospital\n-\nLinfen, Shanxi, Porcelana\n- The Third People's Hospital of Linfen City\n-\nTaiyuan, Shanxi, Porcelana\n- Shanxi Bethune Hospital\n-\nTaiyuan, Shanxi, Porcelana\n- Taiyuan Third People's Hospital\n-\n-\nSichuan\n-\nChengdu, Sichuan, Porcelana\n- Hospital of the Chengdu Office of the People's Government of Tibet Autonomous Region\n-\nYibin, Sichuan, Porcelana\n- Yibin First People's Hospital\n-\n-\nTianjin\n-\nTianjin, Tianjin, Porcelana\n- Tianjin Second People's Hospital\n-\nTianjin, Tianjin, Porcelana\n- Tianjin Third Central Hospital\n-\n-\nTibet\n-\nLasa, Tibet, Porcelana\n- The Third People's Hospital of Tibet Autonomous Region\n-\n-\nYunnan\n-\nKunming, Yunnan, Porcelana\n- The First People's Hospital of Yunnan Province\n-\nKunming, Yunnan, Porcelana\n- Affiliated Hospital of Yunnan University\n-\n-\nZhejiang\n-\nLishui, Zhejiang, Porcelana\n- The Central Hospital of Lishui City\n-\nNingbo, Zhejiang, Porcelana\n- Beilun Hospital of Traditional Chinese Medicine\n-\nYiwu, Zhejiang, Porcelana\n- The Fourth Affiliated Hospital of Zhejiang University\n-\n-\nCriterios de participaci\u00f3n\nLos investigadores buscan personas que se ajusten a una determinada descripci\u00f3n, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.\nCriterio de elegibilidad\nEdades elegibles para estudiar\n18 a\u00f1os y mayores (Adulto, Adulto Mayor)\nAcepta Voluntarios Saludables\nNo\nM\u00e9todo de muestreo\nMuestra no probabil\u00edstica\nPoblaci\u00f3n de estudio\nPoblaciones con enfermedad hep\u00e1tica que completan el ciclo completo de vacunaci\u00f3n contra el COVID-19\nDescripci\u00f3n\nCriterios de inclusi\u00f3n:\n- Diagnosticado cl\u00ednica o patol\u00f3gicamente con enfermedad hep\u00e1tica preexistente, incluyendo: enfermedad hep\u00e1tica cr\u00f3nica, cirrosis, c\u00e1ncer de h\u00edgado, sujetos trasplantados de h\u00edgado, etc.;\n- Recibir el ciclo completo de vacunaci\u00f3n contra el COVID-19 durante 14 d\u00edas o m\u00e1s;\n- Ofr\u00e9zcase como voluntario para participar en este estudio.\nCriterio de exclusi\u00f3n:\n- Menores de 18 a\u00f1os;\n- Mujeres durante el embarazo o la lactancia;\n- Investigaci\u00f3n sobre otras situaciones consideradas no aptas para la selecci\u00f3n.\nPlan de estudios\nEsta secci\u00f3n proporciona detalles del plan de estudio, incluido c\u00f3mo est\u00e1 dise\u00f1ado el estudio y qu\u00e9 mide el estudio.\n\u00bfC\u00f3mo est\u00e1 dise\u00f1ado el estudio?\nDetalles de dise\u00f1o\n\u00bfQu\u00e9 mide el estudio?\nMedidas de resultado primarias\n|\n|\nMedida de resultado\n|\n|\nPeriodo de tiempo\n|\n|\nN\u00famero de participantes con eventos adversos dentro de los 7 d\u00edas posteriores a cada inyecci\u00f3n\nPeriodo de tiempo: hasta 7 d\u00edas despu\u00e9s de cada inyecci\u00f3n\n|\n|\nhasta 7 d\u00edas despu\u00e9s de cada inyecci\u00f3n\nMedidas de resultado secundarias\n|\n|\nMedida de resultado\n|\n|\nPeriodo de tiempo\n|\n|\nIncidencia general de reacciones adversas dentro de los 28 d\u00edas seg\u00fan lo evaluado por CTCAE v4.0\nPeriodo de tiempo: hasta 28 d\u00edas despu\u00e9s de cada inyecci\u00f3n\n|\n|\nhasta 28 d\u00edas despu\u00e9s de cada inyecci\u00f3n\n|\n|\nTasa de conversi\u00f3n serol\u00f3gica de anticuerpos en poblaciones con enfermedad hep\u00e1tica despu\u00e9s de la vacunaci\u00f3n contra el COVID-19\nPeriodo de tiempo: el d\u00eda de la primera dosis de vacunaci\u00f3n (l\u00ednea de base) y 14 d\u00edas, 28 d\u00edas, 90 d\u00edas y 180 d\u00edas despu\u00e9s de la segunda dosis de vacunaci\u00f3n\n|\n|\nel d\u00eda de la primera dosis de vacunaci\u00f3n (l\u00ednea de base) y 14 d\u00edas, 28 d\u00edas, 90 d\u00edas y 180 d\u00edas despu\u00e9s de la segunda dosis de vacunaci\u00f3n\n|\n|\nT\u00edtulos de anticuerpos neutralizantes en muestras de sangre despu\u00e9s de la vacunaci\u00f3n\nPeriodo de tiempo: el d\u00eda de la primera dosis de vacunaci\u00f3n (l\u00ednea de base) y 14 d\u00edas, 28 d\u00edas, 90 d\u00edas y 180 d\u00edas despu\u00e9s de la segunda dosis de vacunaci\u00f3n\n|\n|\nel d\u00eda de la primera dosis de vacunaci\u00f3n (l\u00ednea de base) y 14 d\u00edas, 28 d\u00edas, 90 d\u00edas y 180 d\u00edas despu\u00e9s de la segunda dosis de vacunaci\u00f3n\n|\n|\nT\u00edtulos de anticuerpos IgM en muestras de sangre despu\u00e9s de la vacunaci\u00f3n\nPeriodo de tiempo: el d\u00eda de la primera dosis de vacunaci\u00f3n (l\u00ednea de base) y 14 d\u00edas, 28 d\u00edas, 90 d\u00edas y 180 d\u00edas despu\u00e9s de la segunda dosis de vacunaci\u00f3n\n|\n|\nel d\u00eda de la primera dosis de vacunaci\u00f3n (l\u00ednea de base) y 14 d\u00edas, 28 d\u00edas, 90 d\u00edas y 180 d\u00edas despu\u00e9s de la segunda dosis de vacunaci\u00f3n\n|\n|\nT\u00edtulos de anticuerpos IgG en muestras de sangre despu\u00e9s de la vacunaci\u00f3n\nPeriodo de tiempo: el d\u00eda de la primera dosis de vacunaci\u00f3n (l\u00ednea de base) y 14 d\u00edas, 28 d\u00edas, 90 d\u00edas y 180 d\u00edas despu\u00e9s de la segunda dosis de vacunaci\u00f3n\n|\n|\nel d\u00eda de la primera dosis de vacunaci\u00f3n (l\u00ednea de base) y 14 d\u00edas, 28 d\u00edas, 90 d\u00edas y 180 d\u00edas despu\u00e9s de la segunda dosis de vacunaci\u00f3n\nColaboradores e Investigadores\nAqu\u00ed es donde encontrar\u00e1 personas y organizaciones involucradas en este estudio.\nColaboradores\nPublicaciones y enlaces \u00fatiles\nLa persona responsable de ingresar informaci\u00f3n sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.\nPublicaciones Generales\n-\n[Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, Diemert D, Spector SA, Rouphael N, Creech CB, McGettigan J, Khetan S, Segall N, Solis J, Brosz A, Fierro C, Schwartz H, Neuzil K, Corey L, Gilbert P, Janes H, Follmann D, Marovich M, Mascola J, Polakowski L, Ledgerwood J, Graham BS, Bennett H, Pajon R, Knightly C, Leav B, Deng W, Zhou H, Han S, Ivarsson M, Miller J, Zaks T; COVE Study Group. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med. 2021 Feb 4;384(5):403-416. doi: 10.1056/NEJMoa2035389. Epub 2020 Dec 30.](https://ichgcp.net/es/clinical-trials-registry/publications/5604-efficacy-and-safety-of-the-mrna-1273-sars-cov-2-vaccine)\n-\n[Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, Liu L, Shan H, Lei CL, Hui DSC, Du B, Li LJ, Zeng G, Yuen KY, Chen RC, Tang CL, Wang T, Chen PY, Xiang J, Li SY, Wang JL, Liang ZJ, Peng YX, Wei L, Liu Y, Hu YH, Peng P, Wang JM, Liu JY, Chen Z, Li G, Zheng ZJ, Qiu SQ, Luo J, Ye CJ, Zhu SY, Zhong NS; China Medical Treatment Expert Group for Covid-19. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020 Apr 30;382(18):1708-1720. doi: 10.1056/NEJMoa2002032. Epub 2020 Feb 28.](https://ichgcp.net/es/clinical-trials-registry/publications/2989-clinical-characteristics-of-coronavirus-disease-2019-in-china)\n-\n[Xia S, Duan K, Zhang Y, Zhao D, Zhang H, Xie Z, Li X, Peng C, Zhang Y, Zhang W, Yang Y, Chen W, Gao X, You W, Wang X, Wang Z, Shi Z, Wang Y, Yang X, Zhang L, Huang L, Wang Q, Lu J, Yang Y, Guo J, Zhou W, Wan X, Wu C, Wang W, Huang S, Du J, Meng Z, Pan A, Yuan Z, Shen S, Guo W, Yang X. Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes: Interim Analysis of 2 Randomized Clinical Trials. JAMA. 2020 Sep 8;324(10):951-960. doi: 10.1001/jama.2020.15543.](https://ichgcp.net/es/clinical-trials-registry/publications/12334-effect-of-an-inactivated-vaccine-against-sars-cov-2-on-safety-and-immunogenicity-outcomes-interim)\n-\n[Zhang Y, Zeng G, Pan H, Li C, Hu Y, Chu K, Han W, Chen Z, Tang R, Yin W, Chen X, Hu Y, Liu X, Jiang C, Li J, Yang M, Song Y, Wang X, Gao Q, Zhu F. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis. 2021 Feb;21(2):181-192. doi: 10.1016/S1473-3099(20)30843-4. Epub 2020 Nov 17.](https://ichgcp.net/es/clinical-trials-registry/publications/12337-safety-tolerability-and-immunogenicity-of-an-inactivated-sars-cov-2-vaccine-in-healthy-adults-aged)\n-\n[Cornberg M, Buti M, Eberhardt CS, Grossi PA, Shouval D. EASL position paper on the use of COVID-19 vaccines in patients with chronic liver diseases, hepatobiliary cancer and liver transplant recipients. J Hepatol. 2021 Apr;74(4):944-951. doi: 10.1016/j.jhep.2021.01.032. Epub 2021 Feb 6.](https://ichgcp.net/es/clinical-trials-registry/publications/41920-easl-position-paper-on-the-use-of-covid-19-vaccines-in-patients-with-chronic-liver-diseases)\n- World Health Organization. Coronavirus disease (COVID-2019) situation reports[EB/OL]. https: //www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports/.\n-\n[Sarin SK, Choudhury A, Lau GK, Zheng MH, Ji D, Abd-Elsalam S, Hwang J, Qi X, Cua IH, Suh JI, Park JG, Putcharoen O, Kaewdech A, Piratvisuth T, Treeprasertsuk S, Park S, Wejnaruemarn S, Payawal DA, Baatarkhuu O, Ahn SH, Yeo CD, Alonzo UR, Chinbayar T, Loho IM, Yokosuka O, Jafri W, Tan S, Soo LI, Tanwandee T, Gani R, Anand L, Esmail ES, Khalaf M, Alam S, Lin CY, Chuang WL, Soin AS, Garg HK, Kalista K, Batsukh B, Purnomo HD, Dara VP, Rathi P, Al Mahtab M, Shukla A, Sharma MK, Omata M; APASL COVID Task Force, APASL COVID Liver Injury Spectrum Study (APCOLIS Study-NCT 04345640). Pre-existing liver disease is associated with poor outcome in patients with SARS CoV2 infection; The APCOLIS Study (APASL COVID-19 Liver Injury Spectrum Study). Hepatol Int. 2020 Sep;14(5):690-700. doi: 10.1007/s12072-020-10072-8. Epub 2020 Jul 4.](https://ichgcp.net/es/clinical-trials-registry/publications/134597-pre-existing-liver-disease-is-associated-with-poor-outcome-in-patients-with-sars-cov2-infection-the)\n-\n[Iavarone M, D'Ambrosio R, Soria A, Triolo M, Pugliese N, Del Poggio P, Perricone G, Massironi S, Spinetti A, Buscarini E, Vigano M, Carriero C, Fagiuoli S, Aghemo A, Belli LS, Luca M, Pedaci M, Rimondi A, Rumi MG, Invernizzi P, Bonfanti P, Lampertico P. High rates of 30-day mortality in patients with cirrhosis and COVID-19. J Hepatol. 2020 Nov;73(5):1063-1071. doi: 10.1016/j.jhep.2020.06.001. Epub 2020 Jun 9.](https://ichgcp.net/es/clinical-trials-registry/publications/158377-high-rates-of-30-day-mortality-in-patients-with-cirrhosis-and-covid-19)\n-\n[Qi X, Wang J, Li X, Wang Z, Liu Y, Yang H, Li X, Shi J, Xiang H, Liu T, Kawada N, Maruyama H, Jiang Z, Wang F, Takehara T, Rockey DC, Sarin SK; COVID-Cirrhosis-CHESS Group. Clinical course of COVID-19 in patients with pre-existing decompensated cirrhosis: initial report from China. Hepatol Int. 2020 Jul;14(4):478-482. doi: 10.1007/s12072-020-10051-z. Epub 2020 May 22.](https://ichgcp.net/es/clinical-trials-registry/publications/134599-clinical-course-of-covid-19-in-patients-with-pre-existing-decompensated-cirrhosis-initial-report)\n-\n[Moon AM, Webb GJ, Aloman C, Armstrong MJ, Cargill T, Dhanasekaran R, Genesca J, Gill US, James TW, Jones PD, Marshall A, Mells G, Perumalswami PV, Qi X, Su F, Ufere NN, Barnes E, Barritt AS, Marjot T. High mortality rates for SARS-CoV-2 infection in patients with pre-existing chronic liver disease and cirrhosis: Preliminary results from an international registry. J Hepatol. 2020 Sep;73(3):705-708. doi: 10.1016/j.jhep.2020.05.013. Epub 2020 May 21. No abstract available.](https://pubmed.ncbi.nlm.nih.gov/32446714)\n-\n[Qi X, Liu Y, Wang J, Fallowfield JA, Wang J, Li X, Shi J, Pan H, Zou S, Zhang H, Chen Z, Li F, Luo Y, Mei M, Liu H, Wang Z, Li J, Yang H, Xiang H, Li X, Liu T, Zheng MH, Liu C, Huang Y, Xu D, Li X, Kang N, He Q, Gu Y, Zhang G, Shao C, Liu D, Zhang L, Li X, Kawada N, Jiang Z, Wang F, Xiong B, Takehara T, Rockey DC; COVID-Cirrhosis-CHESS Group. Clinical course and risk factors for mortality of COVID-19 patients with pre-existing cirrhosis: a multicentre cohort study. Gut. 2021 Feb;70(2):433-436. doi: 10.1136/gutjnl-2020-321666. Epub 2020 May 20. No abstract available.](https://ichgcp.net/es/clinical-trials-registry/publications/134600-clinical-course-and-risk-factors-for-mortality-of-covid-19-patients-with-pre-existing-cirrhosis-a)\n-\n[He Q, Zhang G, Gu Y, Wang J, Tang Q, Jiang Z, Shao C, Zhang H, Chen Z, Ma B, Liu D, Xie G, Xu D, Huang Y, Zhang H, Liang M, Huang H, Wang Y, Liu H, Yang J, Pan H, Zou S, Li F, Wang F, Liu C, Wang W, Xiong B, Li X, Liu L, Yang J, Qi X. Clinical Characteristics of COVID-19 Patients With Pre-existing Hepatitis B Virus Infection: A Multicenter Report. Am J Gastroenterol. 2021 Feb 1;116(2):420-421. doi: 10.14309/ajg.0000000000000924. No abstract available.](https://pubmed.ncbi.nlm.nih.gov/32925195)\nFechas de registro del estudio\nEstas fechas rastrean el progreso del registro del estudio y los env\u00edos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los est\u00e1ndares de control de calidad espec\u00edficos antes de publicarlos en el sitio web p\u00fablico.\nFechas importantes del estudio\nInicio del estudio (Actual)\n11 de mayo de 2021\nFinalizaci\u00f3n primaria (Actual)\n1 de enero de 2022\nFinalizaci\u00f3n del estudio (Actual)\n1 de mayo de 2022\nFechas de registro del estudio\nEnviado por primera vez\n29 de abril de 2021\nPrimero enviado que cumpli\u00f3 con los criterios de control de calidad\n11 de mayo de 2021\nPublicado por primera vez (Actual)\n12 de mayo de 2021\nActualizaciones de registros de estudio\n\u00daltima actualizaci\u00f3n publicada (Actual)\n25 de abril de 2023\n\u00daltima actualizaci\u00f3n enviada que cumpli\u00f3 con los criterios de control de calidad\n23 de abril de 2023\n\u00daltima verificaci\u00f3n\n1 de abril de 2023\nM\u00e1s informaci\u00f3n\nT\u00e9rminos relacionados con este estudio\nT\u00e9rminos MeSH relevantes adicionales\n-\n[Enfermedades del Sistema Digestivo](https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Digestive%20System%20Diseases)\n-\n[Infecciones por coronavirus](https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Coronavirus%20Infections)\n-\n[Infecciones por coronaviridae](https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Coronaviridae%20Infections)\n-\n[Infecciones por Nidovirales](https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Nidovirales%20Infections)\n-\n[Infecciones por virus de ARN](https://ichgcp.net/es/clinical-trials-registry/research/list?cond=RNA%20Virus%20Infections)\n-\n[Enfermedades virales](https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Virus%20Diseases)\n-\n[Infecciones](https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Infections)\n-\n[Infecciones del Tracto Respiratorio](https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Respiratory%20Tract%20Infections)\n-\n[Enfermedades de las v\u00edas respiratorias](https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Respiratory%20Tract%20Diseases)\n-\n[Neumon\u00eda Viral](https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Pneumonia%2C%20Viral)\n-\n[Neumon\u00eda](https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Pneumonia)\n-\n[Enfermedades pulmonares](https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Lung%20Diseases)\n-\n[Enfermedades del HIGADO](https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Liver%20Diseases)\n-\n[COVID-19](https://ichgcp.net/es/clinical-trials-registry/research/list?cond=COVID-19)\nOtros n\u00fameros de identificaci\u00f3n del estudio\n- CHESS2101\nPlan de datos de participantes individuales (IPD)\n\u00bfPlanea compartir datos de participantes individuales (IPD)?\nINDECISO\nInformaci\u00f3n sobre medicamentos y dispositivos, documentos del estudio\nEstudia un producto farmac\u00e9utico regulado por la FDA de EE. UU.\nNo\nEstudia un producto de dispositivo regulado por la FDA de EE. UU.\nNo\nEsta informaci\u00f3n se obtuvo directamente del sitio web\n[clinicaltrials.gov](https://clinicaltrials.gov) sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comun\u00edquese con [register@clinicaltrials.gov](mailto:register@clinicaltrials.gov). Tan pronto como se implemente un cambio en [clinicaltrials.gov](https://clinicaltrials.gov), tambi\u00e9n se actualizar\u00e1 autom\u00e1ticamente en nuestro sitio web. .\nEnsayos cl\u00ednicos sobre COVID-19\n-\nNCT06042530ReclutamientoDeterioro Cognitivo | Condici\u00f3n posterior a COVID-19 | Fatiga Mental\n-\nNCT06039449Reclutamiento\n-\nNCT06038617A\u00fan no reclutandoFiebre | Fiebre despu\u00e9s de la vacunaci\u00f3n | Convulsiones Fiebre\n-\nNCT06038682Reclutamiento\n-\nNCT06036134A\u00fan no reclutandoSalud Conocimiento, Actitudes, Pr\u00e1ctica | Pandemia de COVID-19 | Enfermedades prevenibles por vacunaci\u00f3n | Comportamiento relacionado con la salud | Narraci\u00f3n\n-\nNCT06036251A\u00fan no reclutandoEstr\u00e9s | Estr\u00e9s, Emocional | Pandemia de COVID-19 | Reacci\u00f3n de estr\u00e9s\n-\nNCT06030414A\u00fan no reclutando\n-\nNCT06032000A\u00fan no reclutando\n[Un estudio de fase 1 para evaluar la seguridad, reactogenicidad e inmunogenicidad de una vacuna de refuerzo contra el SARS-CoV-2 (LEM-mR203) en adultos sanos](https://ichgcp.net/es/clinical-trials-registry/NCT06032000)Contagio de COVID-19 | Reacci\u00f3n adversa a la vacuna COVID-19\n-\nNCT06027229A\u00fan no reclutando\n[Inmunogenicidad humoral y celular recombinante adicional de COVID-19 en poblaciones inmunodeprimidas](https://ichgcp.net/es/clinical-trials-registry/NCT06027229)COVID-19 | Inmunosupresi\u00f3n\n-\nNCT06027255A\u00fan no reclutandoCOVID largo | Disfunci\u00f3n auton\u00f3mica | POTS - S\u00edndrome de taquicardia ortost\u00e1tica postural", "language": null, "image": null, "pagetype": "website", "links": ["https://ichgcp.net/es", "#", "https://ichgcp.net/de", "https://ichgcp.net/", "https://ichgcp.net/es", "https://ichgcp.net/fr", "https://ichgcp.net/it", "https://ichgcp.net/pt", "https://ichgcp.net/ru", "https://ichgcp.net/es/guidance-for-industry-investigator-responsibilities-protecting-the-rights-safety-and-welfare-of-study-subjects", "https://ichgcp.net/es/guidance-for-the-notification-of-serious-breaches-of-gcp-or-the-trial-protocol", "https://ichgcp.net/es/national-statement-on-ethical-conduct-in-human-research-2007-updated-2018-nhmrc-australia", "https://ichgcp.net/es/ministerial-ordinance-on-good-clinical-practice-for-drugs-pharmaceuticals-and-medical-devices-agency-japan", "https://ichgcp.net/es/ich-e-group-of-guidelines", "https://ichgcp.net/es/cro-list", "https://ichgcp.net/es/clinical-trials-registry", "https://ichgcp.net/es/eu-clinical-trials-registry", "https://ichgcp.net/es/pharma-list", "https://ichgcp.net/es/labs", "https://ichgcp.net/es/service-companies", "https://ichgcp.net/es/events", "https://ichgcp.net/es/clinical-trials-registry/publications", "https://ichgcp.net/es/clinical-trials-registry/researchers", "https://ichgcp.net/es/cra-jobs", "https://ichgcp.net/es/publications", "https://ichgcp.net/es/news", "https://ichgcp.net/clinical-trials-registry/NCT04883177", "https://telegram.me/share/url?url=https://ichgcp.net/es/clinical-trials-registry/NCT04883177&text=", "https://twitter.com/intent/tweet?url=https://ichgcp.net/es/clinical-trials-registry/NCT04883177", "https://ichgcp.net/es", "https://ichgcp.net/es/clinical-trials-registry", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Hepatopancreatobiliary%20Surgery%20Institute%20of%20Gansu%20Province", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=COVID-19", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Vaccine%20Reaction", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Liver%20Disease", "mailto:wangjt302@163.com?subject=NCT04883177, CHESS2101, Effectiveness and Safety of the COVID-19 Vaccination for Patients With Liver Disease (CHESS2101)", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Hepatopancreatobiliary%20Surgery%20Institute%20of%20Gansu%20Province", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=The%20First%20Affiliated%20Hospital%20of%20Anhui%20Medical%20University", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=LanZhou%20University", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Beijing%20YouAn%20Hospital", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Huashan%20Hospital", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Shandong%20Provincial%20Hospital", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Henan%20Provincial%20People%27s%20Hospital", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Third%20Affiliated%20Hospital%2C%20Sun%20Yat-Sen%20University", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Tianjin%20Third%20Central%20Hospital", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=The%20Central%20Hospital%20of%20Lishui%20City", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=First%20Affiliated%20Hospital%20of%20Chongqing%20Medical%20University", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=The%20First%20Affiliated%20Hospital%20of%20Xiamen%20University", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=The%20First%20People%27s%20Hospital%20of%20Yunnan", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=The%20First%20People%27s%20Hospital%20of%20Taicang", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Tianjin%20Second%20People%27s%20Hospital", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=People%27s%20Hospital%20of%20Ningxia%20Hui%20Autonomous%20Region", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=The%20Third%20People%27s%20Hospital%20of%20Taiyuan", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=The%20Third%20People%27s%20Hospital%20of%20Linfen%20City", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Shanxi%20Bethune%20Hospital", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Jingzhou%20Central%20Hospital", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Hospital%20of%20the%20Chengdu%20Office%20of%20the%20People%27s%20Government%20of%20Tibet%20Autonomous%20Region", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Jincheng%20People%27s%20Hospital", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Fuling%20Central%20Hospital%20of%20Chongqing%20City", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Baoding%20People%27s%20Hospital", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=The%20Third%20People%27s%20Hospital%20of%20Tibet%20Autonomous%20Region", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=The%20Sixth%20People%27s%20Hospital%20of%20Shenyang%20City", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Xingtai%20City%20People%27s%20Hospital", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Jinchang%20Central%20Hospital", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=The%20Third%20People%27s%20Hospital%20of%20Zhenjiang%20City", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Wuhan%20Jinyintan%20Hospital", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Yibin%20First%20People%27s%20Hospital", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Wuxi%20Fifth%20People%27s%20Hospital", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Qingyang%20People%27s%20Hospital", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Beilun%20Hospital%20of%20Traditional%20Chinese%20Medicine", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Qingdao%20Sixth%20People%27s%20Hospital", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Qishan%20Hospital%20of%20Yantai%20City", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Affiliated%20Hospital%20of%20Yunnan%20University", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=The%20Fourth%20Affiliated%20Hospital%20of%20Zhejiang%20University", "https://ichgcp.net/es/clinical-trials-registry/publications/5604-efficacy-and-safety-of-the-mrna-1273-sars-cov-2-vaccine", "https://ichgcp.net/es/clinical-trials-registry/publications/2989-clinical-characteristics-of-coronavirus-disease-2019-in-china", "https://ichgcp.net/es/clinical-trials-registry/publications/12334-effect-of-an-inactivated-vaccine-against-sars-cov-2-on-safety-and-immunogenicity-outcomes-interim", "https://ichgcp.net/es/clinical-trials-registry/publications/12337-safety-tolerability-and-immunogenicity-of-an-inactivated-sars-cov-2-vaccine-in-healthy-adults-aged", "https://ichgcp.net/es/clinical-trials-registry/publications/41920-easl-position-paper-on-the-use-of-covid-19-vaccines-in-patients-with-chronic-liver-diseases", "https://ichgcp.net/es/clinical-trials-registry/publications/134597-pre-existing-liver-disease-is-associated-with-poor-outcome-in-patients-with-sars-cov2-infection-the", "https://ichgcp.net/es/clinical-trials-registry/publications/158377-high-rates-of-30-day-mortality-in-patients-with-cirrhosis-and-covid-19", "https://ichgcp.net/es/clinical-trials-registry/publications/134599-clinical-course-of-covid-19-in-patients-with-pre-existing-decompensated-cirrhosis-initial-report", "https://pubmed.ncbi.nlm.nih.gov/32446714", "https://ichgcp.net/es/clinical-trials-registry/publications/134600-clinical-course-and-risk-factors-for-mortality-of-covid-19-patients-with-pre-existing-cirrhosis-a", "https://pubmed.ncbi.nlm.nih.gov/32925195", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Digestive%20System%20Diseases", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Coronavirus%20Infections", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Coronaviridae%20Infections", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Nidovirales%20Infections", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=RNA%20Virus%20Infections", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Virus%20Diseases", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Infections", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Respiratory%20Tract%20Infections", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Respiratory%20Tract%20Diseases", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Pneumonia%2C%20Viral", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Pneumonia", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Lung%20Diseases", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Liver%20Diseases", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=COVID-19", "https://clinicaltrials.gov", "mailto:register@clinicaltrials.gov", "https://clinicaltrials.gov", "https://ichgcp.net/es/clinical-trials-registry/NCT06042530", "https://ichgcp.net/es/clinical-trials-registry/NCT06039449", "https://ichgcp.net/es/clinical-trials-registry/NCT06038617", "https://ichgcp.net/es/clinical-trials-registry/NCT06038682", "https://ichgcp.net/es/clinical-trials-registry/NCT06036134", "https://ichgcp.net/es/clinical-trials-registry/NCT06036251", "https://ichgcp.net/es/clinical-trials-registry/NCT06030414", "https://ichgcp.net/es/clinical-trials-registry/NCT06032000", "https://ichgcp.net/es/clinical-trials-registry/NCT06027229", "https://ichgcp.net/es/clinical-trials-registry/NCT06027255", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Pfizer", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Center%2Bfor%2BIndustrial%2BTechnological%2BDevelopment%2Bof%2BSpain", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=SeeCure%2BLLC", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=National%2BCancer%2BInstitute%2B%2528NCI%2529", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Universidad%2Bdel%2BZulia", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Orphanetics%2BPharma%2BEntwicklungs%2BGmbH", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Cairo%2BUniversity", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=European%2BSociety%2Bof%2BHuman%2BReproduction%2Band%2BEmbryology", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Kaneka%2BAmericas%2BHolding%2BInc.", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=GlaxoSmithKline", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=M.D.%2BAnderson%2BCancer%2BCenter", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=AstraZeneca", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Universidade%2Bde%2BLisboa%252C%2BPortugal", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Mayo%2BClinic", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Novartis%2BPharmaceuticals", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Medtronic%2BSurgical%2BTechnologies", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Jos%25C3%25A9phine%2BSOLTANI%252C%2BCardiology%2Bdepartment%252C%2BVersailles%2BHospital", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Assistance%2BPublique%2B-%2BH%25C3%25B4pitaux%2Bde%2BParis", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Pediatric%2BOrthopaedic%2BSociety%2Bof%2BNorth%2BAmerica", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Assiut%2BUniversity", "https://ichgcp.net/es/clinical-trials-registry/research/browse/spns_alpha_all", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Hypertension", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Pain", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Stage%2BI%2BGallbladder%2BCancer%2BAJCC%2Bv8", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Malignant%2BNeoplasm%2Bof%2BRespiratory%2Band%2BIntrathoracic%2BOrgan%2BCarcinoma", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Cushing%2527s%2BSyndrome%2BI", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Asthma", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Stroke", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Prostate%2BCancer", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Colon%2BMalignant%2BTumor", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Carcinoma%252C%2BAdrenal%2BCortical", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Depression", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Coronary%2BArtery%2BDisease", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Breast%2BCancer", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Ankle%2BArthroplasty", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=HIV%2BInfections", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Post-traumatic%2BAnosmia", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Obesity", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Ultrasound%2BEvaluation", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Esophageal%2BResection%2BCandidates", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Postneoadjuvant%2BTherapy%2BStage%2BI%2BGastric%2BCancer%2BAJCC%2Bv8", "https://ichgcp.net/es/clinical-trials-registry/research/browse/cond_alpha_all", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Pilocarpine%2B1.25%2525%2BEye%2Bdrop", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Dexamethasone", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Cisplatin", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Injectafer", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Carboplatin", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=20mg%2BAzilsartan%2BTablets", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Brimonidine%2Btartrate%2Bophthalmic%2Bsolution%2B0.025%2525%2B%2528n%2B%253D%2B56%2529", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Transplant%2B2%2BMelphalan", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Valacyclovir%2Barrow", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Teicoplanin%2BSandoz%2B200%2Bmg%2Bpowder%2Band%2Bsolvent%2Bfor%2Bsolution%2Bfor%2Binjection%2Bor%2Binfusion%2Bor%2Boral%2Bsolution.", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Alpelisib%2B150%2BMG%2BOral%2BTablet%2B%255BPiqray%255D", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Bevacizumab", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=MK-8521%2B100%25CE%25BCg", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Oral%2BGlucose%2BGel", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Docetaxel", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Paclitaxel", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Capecitabine", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Gemcitabine", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Prednisone", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Cyclophosphamide", "https://ichgcp.net/es/clinical-trials-registry/research/browse/intr_alpha_all", "https://ichgcp.net/es/cro-list/country/angola", "https://ichgcp.net/es/cro-list/country/argentina", "https://ichgcp.net/es/cro-list/country/armenia", "https://ichgcp.net/es/cro-list/country/dominican_republic", "https://ichgcp.net/es/cro-list/country/finland", "https://ichgcp.net/es/cro-list/country/kuwait", "https://ichgcp.net/es/cro-list/country/mauritius", "https://ichgcp.net/es/cro-list/country/mexico", "https://ichgcp.net/es/cro-list/country/qatar", "https://ichgcp.net/es/cro-list/country/saudi_arabia", "https://ichgcp.net/es/cro-list/country/senegal", "https://ichgcp.net/es/cro-list/country/sri_lanka", "https://ichgcp.net/es/cro-list/country/sweden", "https://ichgcp.net/es/cro-list", "https://ichgcp.net/es/cro-list/country/gabon/company/sgs", "https://ichgcp.net/es/cro-list/country/gabon", "https://ichgcp.net/es/clinical-trials-registry/research/browse/cond_alpha_all", "https://ichgcp.net/es/clinical-trials-registry/research/browse/cond_cat", "https://ichgcp.net/es/clinical-trials-registry/research/browse/ord_alpha_all", "https://ichgcp.net/es/clinical-trials-registry/research/browse/intr_alpha_all", "https://ichgcp.net/es/clinical-trials-registry/research/browse/intr_cat", "https://ichgcp.net/es/clinical-trials-registry/research/browse/diet_alpha_all", "https://ichgcp.net/es/clinical-trials-registry/research/browse/diet_cat", "https://ichgcp.net/es/clinical-trials-registry/research/browse/spns_alpha_all", "https://ichgcp.net/es/clinical-trials-registry/research/browse/spns_cat", "https://ichgcp.net/es/clinical-trials-registry/research/browse/locn_alpha_all", "https://ichgcp.net/es/clinical-trials-registry/research/browse/locn_cat", "https://ichgcp.net/es", "https://ichgcp.net/es/guidance-for-industry-investigator-responsibilities-protecting-the-rights-safety-and-welfare-of-study-subjects", "https://ichgcp.net/es/guidance-for-the-notification-of-serious-breaches-of-gcp-or-the-trial-protocol", "https://ichgcp.net/es/national-statement-on-ethical-conduct-in-human-research-2007-updated-2018-nhmrc-australia", "https://ichgcp.net/es/ministerial-ordinance-on-good-clinical-practice-for-drugs-pharmaceuticals-and-medical-devices-agency-japan", "https://ichgcp.net/es/guideline-for-the-notification-of-serious-breaches-of-regulation-eu-no-536-2014", "https://ichgcp.net/es/cro-list", "https://ichgcp.net/es/pharma-list", "https://ichgcp.net/es/labs", "https://ichgcp.net/es/service-companies", "https://ichgcp.net/es/cra-jobs", "https://ichgcp.net/es/clinical-trials-registry", "https://ichgcp.net/es/eu-clinical-trials-registry", "https://ichgcp.net/es/publications", "https://ichgcp.net/es/news", "https://ichgcp.net/about-us-our-mission", "https://ichgcp.net/es/sitemap", "https://ichgcp.net/es/contact-us", "https://ichgcp.net/es/feed", "/privacy", "/disclaimer", "https://ichgcp.net/da/clinical-trials-registry/NCT04883177", "https://ichgcp.net/de/clinical-trials-registry/NCT04883177", "https://ichgcp.net/clinical-trials-registry/NCT04883177", "https://ichgcp.net/es/clinical-trials-registry/NCT04883177", "https://ichgcp.net/fr/clinical-trials-registry/NCT04883177", "https://ichgcp.net/it/clinical-trials-registry/NCT04883177", "https://ichgcp.net/hu/clinical-trials-registry/NCT04883177", "https://ichgcp.net/nl/clinical-trials-registry/NCT04883177", "https://ichgcp.net/no/clinical-trials-registry/NCT04883177", "https://ichgcp.net/pl/clinical-trials-registry/NCT04883177", "https://ichgcp.net/pt/clinical-trials-registry/NCT04883177", "https://ichgcp.net/fi/clinical-trials-registry/NCT04883177", "https://ichgcp.net/sv/clinical-trials-registry/NCT04883177", "https://ichgcp.net/cs/clinical-trials-registry/NCT04883177", "https://ichgcp.net/ru/clinical-trials-registry/NCT04883177", "https://ichgcp.net/ja/clinical-trials-registry/NCT04883177", "https://ichgcp.net/zh/clinical-trials-registry/NCT04883177", "https://ichgcp.net/ko/clinical-trials-registry/NCT04883177", "https://ichgcp.net/pdf/privacy_cookies_policy.pdf", "https://ichgcp.net/pdf/terms_of_service.pdf", "https://ichgcp.net/pdf/privacy_cookies_policy.pdf", "https://ichgcp.net/pdf/terms_of_service.pdf"]}